Elliptocytosis 2 C1851741
A genetic condition causing elliptically shaped red blood cells. Often mild with few or no symptoms. Management focuses on monitoring blood health.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Abdominal discomfort
(hematologic)Generalized symptoms
(hematologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Pale skin
(hematologic)Yellowish sclera
(hematologic)Exercise intolerance
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Regular blood monitoring
Periodic complete blood count and reticulocyte count to monitor for progression of hemolysis. Most mild elliptocytosis cases remain stable without intervention.
Folate supplementation
Adequate folate intake supports erythropoiesis and may reduce symptoms. Foods rich in folate include leafy greens, legumes, and fortified cereals.
Additional treatment options
Avoidance of oxidative stressors
Reduce exposure to drugs, chemicals, and environmental factors that may trigger oxidative stress and exacerbate hemolysis in susceptible individuals.
lifestyleIron monitoring and management
Although hemolysis typically does not cause iron deficiency, periodic iron studies may be warranted. Holistic approaches to support overall blood health may be explored.
complementarySplenectomy consideration
Reserved for rare cases with severe chronic hemolysis and significant symptoms. Requires careful risk-benefit analysis as elliptocytosis is typically benign.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elliptocytosis 2 C1851741?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Gallagher PG, Dzierzak E,统一的。 Guidelines for the Diagnosis and Management of Hereditary Red Cell Membrane Disorders. Blood Rev. 2022.
Da Costa L, Mohandas N, Sorette M. Red Blood Cell Membrane Protein Defects in Hereditary Elliptocytosis. Hematology Am Soc Hematol Educ Program. 2021.
An X, Mohandas N. The Red Cell Membrane. In: Kaushansky K, editor. Williams Hematology, 10th ed. McGraw-Hill; 2023. p. 245-312.
Narla J, Mohandas N. Clinical Manifestations and Management of Hereditary Spherocytosis and Elliptocytosis. Clin Hematol Int. 2020.
Medication Comparisons
Compare medications used to treat Elliptocytosis 2 C1851741. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy